Drug Res (Stuttg) 2015; 65(3): 158-163
DOI: 10.1055/s-0034-1375646
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Synthesis of Novel N-(4-benzoylphenyl)-2-furamide Derivatives and their Pharmacological Evaluation as Potent Antihyperlipidemic Agents in Rats

T. Al-Qirim
1  Faculty of Pharmacy, Al-Zaytoonah University, Amman, Jordan
,
G. Shattat
1  Faculty of Pharmacy, Al-Zaytoonah University, Amman, Jordan
,
G. A. Sheikha
1  Faculty of Pharmacy, Al-Zaytoonah University, Amman, Jordan
,
K. Sweidan
2  Department of Chemistry, Faculty of Science, University of Jordan, Amman, Jordan
,
Y. Al-Hiari
3  Faculty of Pharmacy, University of Jordan, Amman, Jordan
,
A. Jarab
1  Faculty of Pharmacy, Al-Zaytoonah University, Amman, Jordan
› Author Affiliations
Further Information

Publication History

received 07 January 2014

accepted 21 April 2014

Publication Date:
21 May 2014 (online)

Abstract

In the search for new potential antihyperlipidemic agents, the present study focuses on the synthesis and pharmacological activity of a series of novel N-(4-benzoylphenyl)-2-furamides (3a–3e). Hyperlipidemia was induced in rats by single intraperitoneal injection of Triton WR-1339 (300 mg/kg body weight). At a dose of 15 mg/kg body weight, compounds 3b, 3d and bezafibrate (100 mg/kg) significantly (p<0.0001) reduced elevated plasma triglyceride levels after 18 h compared to the hyperlipidemic control group. However, only groups treated with compounds 3b, and 3d obviously showed a significant (p<0.0001) reduction in plasma total cholesterol levels. Moreover, high density lipoprotein-cholesterol levels were significantly (p<0.0001) increased in animals treated with compounds 3b, 3d and bezafibrate. It is therefore reasonable to assume that compounds 3b and 3d may have promising potential in the treatment of hyperlipidemia. This beneficial activity may contribute to their cardioprotective and antiatherosclerotic role.